Synaffix’s glycan-based antibody–drug conjugate technology is experiencing strong demand, based on its potential to improve safety and efficacy of cancer therapies without genetic engineering.

Global drugmakers are stepping up their search for China‑developed experimental medicines as they cut costs ahead of patent ...

Q4 2025 Earnings Call February 9, 2026 8:30 AM ESTCompany ParticipantsCaspar Tudor - Head of Investor RelationsUdit Batra ...

XMT-1660: A phase 1b trial of a B7-H4 targeted antibody drug conjugate (ADC) in breast, endometrial, and ovarian cancers. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This ...

Regarding the industry's talent pipeline, Dr. de Miguel highlights the importance of education programs in the fields of science, technology, engineering, and mathematics (STEM) in building the ...

Yosemite, a venture capital firm dedicated to making cancer non-lethal through a combination of academic philanthropy and for-profit investing, has deployed more than $18 million in grants through a ...

The study is called the first to assess the effects of pandemic-related disruptions on the short-term survival of cancer ...

Tim Jing, ’26 and Jennifer Hamad, ’25 have been awarded 2026 Churchill Scholarships to pursue graduate study at the University of Cambridge.

U.S.-based biotech stocks are closely watching the China's rapid advance into the biotech field. Will they withstand the ...

The Royal Society of Chemistry is proud to announce that seven of the world's most influential scientists have been awarded ...